- Keros Therapeutics (KROS, Financial) stock has recently increased by 3.7%, closing at $11.44.
- Analyst forecasts suggest a substantial 157% potential upside with a mean price target of $29.40.
- The stock currently holds a Zacks Rank of #2 (Buy), indicating promising momentum.
Keros Therapeutics (KROS) has experienced a recent surge in its stock price by 3.7%, settling at $11.44. This momentum presents an intriguing opportunity for investors, as analysts project a potential upside of 157% with an average price target set at $29.40. While skepticism can often accompany analyst predictions, the increasing earnings estimates coupled with a Zacks Rank #2 (Buy) signal suggest possible positive trends for the stock.
Wall Street Analysts Forecast
According to insights from 9 analysts, the average one-year price target for Keros Therapeutics Inc (KROS, Financial) stands at $29.00, with projections ranging from a high of $41.00 to a low of $15.00. This average target indicates an impressive upside of 180.74% from the current market price of $10.33. For more in-depth estimate data, refer to the Keros Therapeutics Inc (KROS) Forecast page.
Furthermore, the consensus recommendation from 13 brokerage firms places Keros Therapeutics Inc's (KROS, Financial) average brokerage recommendation at 2.1, which suggests an "Outperform" status. This rating is based on a scale where 1 represents a Strong Buy and 5 indicates a Sell, further underscoring the stock's favorable outlook among analysts.
